XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Name: XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
License: Public Domain

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

ClinicalTrials.gov · Datasets · License: Public Domain

tislelizumab, bevacizumab, oxaliplatin, capecitabine, mss/pmmr, metastatic colorectal cancer (mcrc)

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 311133
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.